期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 799, 期 -, 页码 128-134出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejphar.2017.02.016
关键词
Stroke; Angiotensin Type 2 Receptor; Compound 21; Neuroprotection; And Interleukin 10
资金
- Veterans Affairs (VA) Merit Review [BX000891, RO1-NS063965, R21-NS088016]
- VA Merit Award [BX000347]
- VA Research Career Scientist Award
- NIH [R01NS083559]
Introduction: We and others have shown that the angiotensin type 2 (AT2) receptor agonist, compound 21 (C21), provides neuroprotection and enhances recovery in rodent stroke models yet the mechanism involved is not known. Moreover, C21 treatment is associated with an anti-inflammatory response. Here we tested the hypothesis that C21 mediates neuroprotection by upregulating the neuroprotective and anti-inflammatory cytokine, interleukin (IL)-10. Methods: Wistar rats were subjected to 3 h-middle cerebral artery suture occlusion and treated at reperfusion with C21 (0.03 mg/kg) +/- IL-10 neutralizing antibody (0.1 mg/kg) both given i.p. Infarct size, behavioral outcomes, and molecular analysis were performed at 24 h post-injury. Primary rat neurons were used to test the direct neuroprotective effect of C21 in vitro. Results: C21 treatment reduced infarct size, improved functional outcome and decreased the pro-inflammatory cytokine, tumor necrosis factor alpha (TNF-alpha) in the ischemic hemisphere compared to saline. Anti-IL-10 co-treatment blocked the C21-induced reduction in infarct size and inflammation, and the improvement in behavioral outcome. In vitro, C21 treatment increased neuron survival and reduced cell apoptosis after oxygen glucose deprivation (OGD) and OGD/reoxygenation. These effects were mediated through AT2R stimulation. Conclusion: C21 provides direct neuroprotection as well as indirect protection through IL-10.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据